The global obsessive compulsive disorder drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are propelling market growth include increasing R&D investment and a rise in clinical trials by market players, which are expected to fuel the market growth during the forecast period. Obsessive-compulsive disorder (OCD) refers to an anxiety disorder that is characterized by unreasonable and uncontrollable thoughts and fears leading an individual to perform repetitive behaviours. Obsessive-compulsive disorder is a disorder known to compel a person to get stuck on a particular thought or fear. The developments in the treatment, therapies and novel treatment, and advancements in the anti-anxiety, antipsychotic and antidepressant drugs is expected to provide various other opportunities in the OCD drugs market.
To Request a Sample of our Report on Global Obsessive Compulsive Disorder Drugs Market: https://www.omrglobal.com/request-sample/obsessive-compulsive-disorder-drugs-market
The global obsessive compulsive disorder drugs market analysis includes some of the key market players such as Abbott Laboratories, Eli Lilly, and Company, Viatria Inc., H. Lundbeck A/S, Pfizer Inc., among others. In order to maintain a strong position in the market, the market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions. For instance, in August 2021, Alembic Pharmaceuticals declared that it has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Clomipramine Hydrochloride Capsules. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Anafranil Capsules of SpecGX LLC. Clomipramine Hydrochloride Capsules are indicated for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder (OCD). Alembic has a cumulative total of 149 ANDA approvals from USFDA.
Recent Development:
- In August 2020, Sun Pharmaceutical Industries Limited announced that it had launched FluGuard (Favipiravir 200 mg) at an economical price of Rs. 35 per tablet for the treatment of mild to moderate cases of COVID-19 in India. Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate COVID-19 disease. The company is launching FluGuard at an economical price to make the drug accessible to more and more patients, thereby reducing their financial burden. This has supported India’s pandemic response.
- In April 2021, H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced the decision to continue recruiting patients in phase III clinical trial of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer’s type (NCT03548584). The continuation of the study enables Lundbeck and Otsuka to explore further the efficacy of brexpiprazole to address the high medical need in patients suffering from agitation in Alzheimer’s type dementia. The completion of the trial successfully will result in a new product launch, thus impacting the sales and revenue of the company.
- In June 2021, Teva Pharmaceuticals USA, Inc., a US affiliate of Teva Pharmaceutical Industries Ltd. announced the U.S. launch of its generic version once-daily SOOLANTRA (ivermectin) Cream, 1% for the treatment of inflammatory lesions of rosacea. With the launch of products, Teva has become a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area.
A full Report of Global Obsessive Compulsive Disorder Drugs Market is Available @ https://www.omrglobal.com/industry-reports/obsessive-compulsive-disorder-drugs-market
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered
- Regions Covered- Globally
Competitive Landscape: Abbott Laboratories, Eli Lilly, and Company, Viatria Inc., H. Lundbeck A/S, Pfizer Inc., among others.
Global Obsessive Compulsive Disorder Drugs Market Report Segmentation
By Product
- SSRI
- TCA
- Others
Global Obsessive Compulsive Disorder Drugs Market by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/obsessive-compulsive-disorder-drugs-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
